No consistent trigger for her anaphylaxis could be identified on history or specific IgE testing. Bone marrow biopsy, endoscopies and skin biopsies found no evidence of mastocytosis or mastocytoma. Investigations for anaphylaxis mimics were unrevealing. Multiple medications were initiated to control attacks including ketotifen, montelukast, omalizumab and cyclosporin. A multidisciplinary team including psychiatry, speech therapy, occupational therapy, ENT and nursing, were involved in the patient's care. The patient was diagnosed with anxiety disorder and caffeine dependence/toxicity (20 coffees per day). She was commenced on quetiapine, and received training in mindfulness and relaxation techniques. Her caffeine consumption was reduced to two coffees per day. Her clinical improvement coincided with implementation of these medications, lifestyle and psychological strategies. In the 6 weeks following discharge, she had one further episode of anaphylaxis; a significant reduction in symptom frequency.
Our impression was of frequent, generalised idiopathic anaphylaxis, exacerbated by caffeine excess, and anxiety. A multidisciplinary approach was essential to managing this complex case. University of Sydney, Sydney, Australia
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Background: Investigation of perioperative allergic reactions typically includes skin testing and measurement of specific IgE (sIgE) to suspected causative agents. Specific IgE to neuromuscular blocking agents (NMBAs) may be detected via a commercial assay using a morphine substrate as a marker for the substituted ammonium groups considered to be the main allergenic epitopes of NMBAs. This assay has been demonstrated to be effective in detecting sensitisation to suxamethonium and the aminosteroidal NMBAs, however it is unreliable for the benzylisoquinoline agents. A recent study has suggested some in vitro cross-reactivity between benzylisoquinoline NMBAs and the aminosteroidal NMBA rocuronium, in the absence of reactivity to substituted ammonium groups. This analysis was therefore undertaken to determine the effectiveness of the morphine sIgE assay to detect rocuronium-allergic patients.
Methods: Analysis was carried out on morphine sIgE and intradermal skin test results performed for patients investigated at the Royal North Shore Hospital Anaesthetic Allergy Clinic during the period June 2009 to June 2016. Standardised intradermal skin tests were performed with a panel of NMBAs. Measurement of morphine sIgE was performed via the Phadia ImmunoCAP system.
Results:
Of the 422 patients included in the analysis, 130 were skin test positive to NMBAs. A total of 19 patients were skin test positive to rocuronium without additional cross-reactivity to other NMBAs. Morphine sIgE levels below the positive cut-off threshold were seen in 47% of this subgroup, corresponding with a sensitivity of 53% relative to skin testing. This is in contrast to a sensitivity of 75% in patients showing positive skin test results to rocuronium with cross-reactivity involving suxamethonium or other aminosteroidal NMBAs.
Conclusion:
These results may suggest the presence of an additional allergenic epitope on rocuronium, unrelated to the substituted ammonium group. Further studies investigating this possibility would be beneficial in enabling accurate assessment of these patients. 
